Kornimate/medical-research-clean huggingface dataset:
efficacy and mechanisms of low-intensity focused ultrasound on negative symptoms in patients with schizophrenia

Conditions: Negative Symptoms of Schizophrenia

Summary: based on our research background, we hypothesize that lifus has neuromodulation effects on brain cortex and the active lifus on left-dlpfc would improve negative symptoms in schizophrenia patients. it would firstly verify the safety of lifus on human as well. the multimodal mri will be contributed to investigate the possible mechanism of negative symptoms.

firstly, we plan to explore the short-term effects of lifus on cortical excitability by detecting the mep amplitude. 40 patients and relatively well matched healthy-control would be enrolled. after mep detection and baseline evaluations, the two groups will be treated with one-single intervention on the primary motor cortex. the cognitive function and mep amplitude will be assessed respectively at the moment, after 15 minutes and 30 minutes. then, it is a randomized double-blind sham-controlled lifus intervention trial in schizophrenia patients. after screening and baseline evaluations, the 40 patients with schizophrenia will be treated with active lifus or sham stimulation for 3 weeks on the left dlpfc. the multimodal mri will be acquired. clinical symptoms and cognitive function will be assessed respectively at baseline, at the end of fifth treatments and after the end of the treatment.

Eligibility criteria:
* inclusion criteria (patients): 1. meet the dsm-5 diagnostic criteria for schizophrenia or schizoaffective disorder; 2. age18-50, right-handed, han nationality; 3. the score of at least 1 item from n1 to n7 is ≥4 (moderate or above); 4. be in a stable condition, received second-generation antipsychotics for at least 4 weeks or more; 5. written informed consent; * exclusion criteria (patients): 1. current or past neurological illness, severe physical diseases, substance abuse or alcohol dependence, mental retardation, pregnant or lactation; 2. uncooperative or risky patients with high excitement, stupor, disorder of words and deeds, negative suicide, etc.; 3. a history of mect or other physical therapy within 6 months; 4. a history of epilepsy, or epileptic waves on the baseline eeg; 5. ruled out share antiepileptic drugs, carbamazepine, valproic acid salt) or larger doses of benzodiazepines drugs (\> 10 mg/day, diazepam clonazepam 2 mg/day, 1 mg/day, alprazolam lorazepam 2 mg/day, midazolam 10 mg/day, 20 mg/day, mr shah diazepam triazolam 0.5 mg/day), avoid the use of chlorine drug, (in principle, to avoid the use of antiepileptic drugs and clonazepam;other antipsychotic drugs, if necessary, remain unchanged during the course of treatment; 6. contraindications to lifus and mri are present.

Keywords: low-intensity focused ultrasound negative symptoms of schizophrenia patients
conduction system pacing with left bundle branch pacing as compared to standard right ventricular pacing

Conditions: Pacemaker DDD; Heart Block

Summary: high burden right ventricular (rv) pacing has been shown to increase cardiovascular mortality, incidence of heart failure (hf), worsen left ventricular (lv) function and accelerate the development of atrial fibrillation (af). high percentage ventricular pacing and wider paced qrs in the setting of normal baseline lv ejection fractions have consistently been shown to be independent risk factors for pacing-induced cardiomyopathy. left bundle branch pacing (lbbp) has emerged as a potential alternative pacing mechanism that may avoid lv dyssynchrony and pacing-induced lv dysfunction by mimicking native electrical conduction.

we hypothesize that in patients with high degree av block with anticipated ventricular pacing \>90%, and an ef \>35% patients undergoing lbbp will demonstrate a significantly lower number of the primary composite endpoint of cardiovascular death, heart failure events, and change in lvesvi as compared to standard rv pacing. echos will be performed at baseline, 12, 24, and 36 months. ntprobnps are performed at baseline and follow-up. there will be a core echo lab, and blinded adjudication of ecgs and events.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. patients with an ejection fraction of \>35% 3. patients with an indication for ventricular pacing and high-degree atrioventricular block where the degree of anticipated rv pacing is \>90% including: 1. third degree av block 2. symptomatic or asymptomatic second-degree av block 3. first degree av block ≥ 280ms with a narrow qrs, or ≥ 240ms with an intraventricular delay (qrs duration ≥120ms) 4. echocardiogram within the last 3 months, with ability to have dicom images exclusion criteria: 1. indication for an implantable cardioverter defibrillator 2. presence of a mechanical tricuspid valve 3. any prior attempt at implantation of an icd, crt, hbp, or lbbp 4. lack of capacity to consent 5. other serious medical condition with life expectancy of \<2 years 6. pregnancy 7. patients in whom the conduction system abnormality is expected to be transient or recover over time 8. patients with permanent atrial fibrillation

Keywords: left bundle branch pacing
disability in patients with non-specific chronic low back pain

Conditions: Chronic Nonspecific Low Back Pain

Summary: to investigate the reliability and sensitivity of the turkish versions of the roland-morris disability questionnaire, the quebec back pain disability scale, and the oswestry disability index in patients with chronic non-specific low back pain and to increase confidence in their use in clinical practice and research by determining the most appropriate minimal clinically significant difference values for this patient population.

the minimum clinically important difference (mcid) for nonspecific chronic low back pain and disability scales varies depending on the questionnaire used and the method used to assess the mcid. different surveys have been proposed in the areas of pain intensity, disability-specific to low back pain, patient satisfaction with treatment results, and work disability. validated and widely used questionnaires for disability assessment include the roland-morris disability questionnaire (rmdq) the quebec back pain disability scale (qbpds) and the oswestry disability index (odi). these scales are valuable tools for assessing the level of disability and functional limitations in individuals with nonspecific chronic low back pain and play a crucial role in monitoring patients' progress and comparing the effectiveness of different interventions.

Eligibility criteria:
inclusion criteria: * getting diagnosed with chronic non-specific low back pain * being able to read and speak turkish * being between the ages of 18 and 65 * agreeing to participate in the research and signing the voluntary consent form exclusion criteria: * presence of systemic disease * cognitive impairment status (mini-mental state examination \<24), * recent (\<12 weeks) history of myocardial infarction, cerebrovascular accident * presence of radiculopathy, infection, tumor, osteoporosis, vertebral fracture, trauma and surgery in the lumbar region * having received any exercise therapy before * refusal of treatment or failure to comply with treatment

Keywords: chronic low back pain disability minimal clinically significant difference
comparing effect of short sleep duration on weight loss of overweight and obese women attending a weight loss program

Conditions: Obesity; Overweight

Summary: the purpose of the present study is to evaluate the effect of sleep duration on weight loss of obese and overweight adult when they are in a weight loss plan (novindiet protocol). the investigators aim is to compare the effects of short term sleep duration with normal sleep duration with respect to body weight (and abdominal adiposity).


Eligibility criteria:
inclusion criteria: * must be female * must have \< 7 hour sleep per night * must be 18-45 years of age. * must have body mass index (bmi) between 27-35 kg/ m². * must be able to have moderate exercise. * must be interested to have weight loss. exclusion criteria: * participating in a research project involving weight loss or physical activity in the previous six months. * pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * taking medication that could affect metabolism or change body weight. * report heart problems, chest pain, and cancer within the last five years. * smoking * menopause * diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Keywords: caloric restriction weight loss sleep
chemotherapy efficacy and follow-up study of hepatitis b virus infection and reactivation in children with leukemia

Conditions: Reactivation of Hepatitis B Virus

Summary: children with clinically diagnosed leukemia may experience occult hbv infection after chemotherapy immunosuppressive therapy, which may affect the normal course of leukemia treatment. however, this is not caused by clinically relevant diagnosis and treatment measures but exists in vivo.

the clinical diagnosis of children with leukemia may be due to the influence of leukemia disease on the immune cells of the children and the damage to the immune system due to immunosuppressive therapy in children. therefore, the risk of contracting hepatitis b virus is relatively high, and some children are in the treatment of immunosuppressive chemotherapy (later), the reactivation of occult hbv infection has an impact on the normal course of leukemia treatment. however, this is not a clinically relevant diagnosis and treatment measure. it is necessary to avoid unnecessary conflicts between clinical doctors and patients as much as possible.

Eligibility criteria:
inclusion criteria: the clinical diagnosis of children with leukemia received systemic chemotherapy. exclusion criteria: children with non-leukemia and children without appropriate treatment.

Keywords: leukemia, occult hepatitis b virus infection
modulation of serca2a of intra-myocytic calcium trafficking in cardiomyopathy secondary to duchenne muscular dystrophy

Conditions: DMD-Associated Dilated Cardiomyopathy

Summary: this research study is testing whether an experimental drug, called srd-001, is safe and helps the weakened heart of patients with duchenne muscular dystrophy (dmd) regain its ability to effectively pump blood to the rest of the body. srd-001 is a form of gene therapy. the goal of srd-001 gene therapy is to provide the heart muscle cells with extra copies of the serca2a gene so that they can produce more serca2a protein to help the heart muscle cells squeeze/contract better. researchers will compare srd-001 treated participants with no-treatment participants; all participants will continue to take their current heart medications. all participants will be followed very closely for 2 years and undergo cardiac magnetic resonance imaging of their heart at baseline, year 1 and year 2 along with assessment of upper limb function and lung function. after the 2 years of close follow-up, all participants will roll over into long-term follow-up where they will be called biannually for information on their current medical status.

this phase 1b, multi-center, non-randomized, open-label, ascending dose escalation, no-intervention-control trial will assess the safety and explore the efficacy of srd-001 administered as a one-time antegrade epicardial coronary artery infusion for the treatment of participants with cardiomyopathy secondary to dmd. srd-001 is an aav1 vector expressing the transgene for serca2a. twelve participants will be assigned to either active treatment with srd-001 or no-intervention based upon their neutralizing antibody status. the objectives of the trial are (1) to evaluate the safety of a one-time intracoronary administration of srd-001 in participants with cardiomyopathy due to dmd; and (2) to explore the impact of srd-001 on heart and skeletal muscle function and quality of life. after screening to determine eligibility, participants will be sequentially assigned to low dose srd-001, high dose srd-001 or no-intervention. participants assigned to active treatment with srd-001 will under cardiac catheterization and angiography just prior to the intracoronary infusion of srd-001 and spend overnight int he hospital for observation.

Eligibility criteria:
inclusion criteria: * diagnosis of dmd with confirmatory genetic testing * cardiomyopathy with left ventricular scar in at least 3 of 16 segments * left ventricular ejection fraction \< 40% * individualized, optimized cardiac medical therapy and glucocorticoid treatment for at least 12 months prior to enrollment * willing and able to provide informed consent exclusion criteria: * abnormal blood pressure * non-dmd-related liver function test elevations * cystatin c ≥ 1.2 mg/l * thrombocytopenia * anemia * inadequate pulmonary function
mi-rna and covid-19

Conditions: COVID-19

Summary: severe acute respiratory syndrome coronavirus 2 (sars-cov-2), the cause of coronavirus disease 2019 (covid-19), induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease, characterized by respiratory failure, shock and multi-organ dysfunction requiring admission in the intensive care unit (icu). the aim of the present study is to analyze mirnas associated with sars-cov-2 infection, disease severity and mortality.


Eligibility criteria:
inclusion criteria: * 18 years * diagnosis of sars-cov-2 infection confirmed by molecular testing on nasopharyngeal swabs exclusion criteria: * pregnant women
the effects of daptomycin and cytokines production in comparison with vancomycin

Conditions: Cellulitis

Summary: primary: to determine the influence of daptomycin on inflammatory cytokine (il-1, tnf and il-6) for the treatment of complicated cellulitis/erysipela compared with alternative treatment (vancomycin or oxacillin). secondary: to evaluate the clinical outcome of both groups according to levels of the cytokines evaluated.


Eligibility criteria:
inclusion criteria: 1. eligible patients will be age between 18 and 65 who required hospitalization and parenteral antimicrobial therapy 2. clinical documentation of cellulitis / erysipela 3. documentation of a minimal surface area 75 cm2 based on the length and / or width of the redness, swelling and / or induration 4. documented fever, defined as oral or tympanic temperature greater than or equal to 38 ° c exclusion criteria: 1. infections and other minor addition of erysipelas / cellulitis 2. any recent use of antibacterial drug therapy (systemic or topical antibacterial drugs within 14 days of enrollment) 3. patients with clinical conditions that alter the interpretation of the primary outcome as patients with neutropenia or compromised immune function, as hiv infection, autoimmune disorders, use of corticosteroids. 4. patients with known or suspected osteomyelitis. 5. patients with suspected or confirmed septic arthritis. 6. patients with complicated skin infections, such as diabetic foot infections. 7. chronic use of antipyretic drugs (eg, daily use of naproxen). 8. less than 18 years of age. 9. pregnancy 10. patients with mixed infections of gram-negative or be deleted since the therapy of gram-negative can influence the levels of cytokines. 11. patients with renal clearance \<30 ml / min. 12. patients who are not susceptible to daptomycin or vancomycin. 13. allergy to study medication.
incidence and outcomes of emergency department patients requiring emergency general surgery

Conditions: Emergency General Surgery

Summary: the objectives of this study were (1) to estimate the incidence of emergency general surgery in a swiss university hospital, (2) to describe the characteristics and outcomes of patients undergoing such interventions, and (3) to study the impact of age on the outcomes.


Eligibility criteria:
inclusion criteria: - consecutive patients visiting the emergency department exclusion criteria: * admitted primarily for a psychiatric reason * left without consultation
factors associated with interdialytic blood pressure variability in maintenance hemodialysis patients

Conditions: Kidney Failure, Chronic

Summary: the purpose of this study is to explore the factors associated with interdialytic blood pressure variability in maintenance hemodialysis patients, especially the association between volume status and blood pressure variability.

hemodialysis patients experience higher rates of cardiovascular morbidity and mortality than the general population and many populations with other chronic diseases. this exceptional risk is explained in part by known risk factors such as diabetes, hypertension, and other uremia-related factors, including vascular calcification and stiffness, autonomic dysfunction, and a high burden of circulating inflammatory mediators. however, additional unidentified risk factors also likely contribute to the disproportionately high prevalence of cardiovascular morbidity in hemodialysis patients. blood pressure variability may represent one plausible cardiovascular risk factor. data from nonuremic human populations show an association between greater blood pressure variability and cardiovascular events,nonfatal cardiovascular events,stroke,and increased left ventricular mass. there has been comparatively little work examining the causes and effects of blood pressure variability in hemodialysis populations. so the purpose of this study is to explore the factors associated with interdialytic blood pressure variability in maintenance hemodialysis patients, especially the association between volume status and blood pressure variability.

Eligibility criteria:
inclusion criteria: * age 18 years or older * receipt of thrice-weekly in-center hemodialysis * no anticipation of imminent(\<6 months)living related kidney transplant * not transfer of care to a nonparticipating facility * no dialytic modality change * free of vascular, infectious, or bleeding complication within 1 month exclusion criteria: * who missed \>2 hemodialysis treatments over 1 month * abused drugs * severe anemia，malnutrition，chronic atrial fibrillation * body mass index of 40 \>kg/m2

Keywords: hemodialysis blood pressure variability volume status
a clinical study comparing the effectiveness and safety of three surgical pathways for laparoscopic total hysterectomy

Conditions: Benign Tumor of Uterus; Surgical Approaches; Enhanced Recovery After Surgery

Summary: to explore the achievement of eras composite indexes within 24 hours after the operation of transumbilical single-hole laparoscopic total hysterectomy, transvaginal laparoscopic total hysterectomy and porous laparoscopic total hysterectomy.

to explore the achievement of eras composite indexes within 24 hours after the operation of transumbilical single-hole laparoscopic total hysterectomy, transvaginal laparoscopic total hysterectomy and porous laparoscopic total hysterectomy.to explore the differences of operation time, intraoperative blood loss, intraoperative conversion mode and postoperative complication rate of three surgical paths: transumbilical single-hole laparoscopic total hysterectomy, transcolposcopic total hysterectomy and porous laparoscopic total hysterectomy.

Eligibility criteria:
inclusion criteria: * 18-60 females * total hysterectomy indications (uterine fibroids, adenomyosis, cervical precancerous lesions, endometrial dysplasia, cervical carcinoma in situ), total hysterectomy is planned * the patients who participated in the study recognized three surgical paths and were willing to accept any of the three at random * be able to understand the research program and voluntarily participate in the research, and sign the informed consent * good compliance, able to cooperate with and provide corresponding clinical information * complete imaging and pathological clinical data; * general condition: ecog≤1; 0 the activity capacity is completely normal, and there is no difference between the activity capacity and that before the onset of the disease; 1 can move about freely and engage in light physical activity, including general household or office work, but cannot engage in heavy physical activity. exclusion criteria: * asexual life history * the cyst needs to be removed at the same time or there are other vulvar, vaginal, appendix and other lesions, and surgical intervention is required at the same time * malignant tumors or highly suspected malignant tumors * history of two or more pelvic surgeries, severe pelvic adhesions(triad examination suspected rectal endometriosis, or poor intrauterine mobility) * history of peritoneal dialysis, pelvic radiotherapy, and previous history of pelvic laparoscopic tuberculosis * the uterus is greater than 3 months of pregnancy or the maximum meridian of the uterus is greater than 12cm according to ultrasound (either of the two conditions can be excluded) * diabetic patients with unsatisfactory blood sugar control * bmi\>30kg/m2 * history of severe mental illness and brain dysfunction * a history of drug abuse or use * patients with poor compliance or who are too far away for adequate follow-up

Keywords: hysterectomy single-port multi-port enhanced recovery after surgery
optimizing open label placebo rationales

Conditions: Chronic Pain

Summary: a 3-arm randomized trial where all chronic pain patients will receive honest placebos, but the information about the placebos will differ between conditions. outcomes are measured for 21 days and a qualitative survey will be conducted.


Eligibility criteria:
inclusion criteria: * chronic pain * 18 years old * english speaking * have a smartphone or computer with video access * taking prescription opioids for chronic pain * the chronic pain is concentrated into the patient's lower back. exclusion criteria: * suspect an allergy to any placebo ingredient * problematic substance use * cancer diagnosis causing pain * anticipated change in opioid script during the study period.
evaluation of a covid-19 rapid diagnostic test in er departments in mexico: a multi-center study

Conditions: Covid19

Summary: an observational (cross-sectional) study in the emergency services of participating hospitals, receiving patients with covid-19 and influenza, aiming to evaluate the diagnostic performance of the rapid antigen detection test for covid-19 both in nasal sampling and saliva, in patients attending emergency services in the 2020-2021 winter season, performed on site, compared to the gold standard (rt-qpcr).

this study aims to analyze the usefulness of rapid tests, especially: a) as a diagnostic test in people attending care for nonspecific, respiratory symptoms, in emergency services of referral hospitals b) as a diagnostic test in contacts of known patients. c) as a diagnostic test to differentiate influenza from covid-19 in the circumstance of an overlap of both viruses in the community. d) in the 3 cases, the gold standard would be the rt-pcr test for influenza and for sars-cov-2 performed in the usual laboratory following the officially approved technique in mexico. if the test were in saliva, it would also be much more accepted and could come close to performing a test at home that would greatly facilitate the diagnosis. so it is important to see the performance of a saliva test. as an observational (cross-sectional) study in the emergency services of participating hospitals, receiving patients with covid-19 and influenza, aiming to evaluate the diagnostic performance of the rapid antigen detection test for covid-19 both in nasal sampling and saliva, in patients attending emergency services in the 2020-2021 winter season, performed on site, compared to the gold standard (rt-qpcr).

Eligibility criteria:
inclusion criteria: * at least 18 years of age * signed informed consent * emergency room visit or screening site with respiratory symptoms consistent with covid-19 / influenza. exclusion criteria: * positive pregnancy test * lactation * decision of the responsible physician to remove patient from the study. * transfer of the patient to another hospital unit

Keywords: rapid test diagnosis antigen test